5-[(1Z)-buta-1,3-dienyl]-6-methyl-2,3-dihydro-1,4-dioxine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二恶英
• 英文名称: 5-[(1Z)-buta-1,3-dienyl]-6-methyl-2,3-dihydro-1,4-dioxine
• 化学式: C₉H₁₂O₂
• 分子量: 152.19
• InChiKey: CSHASDIVUUHAHS-PLNGDYQASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• Diazaspiro ROCK inhibitors
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US11192891B2

  公开（公告）日：2021-12-07

  The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.

  本发明提供了式(I)化合物：或其立体异构体、同系物或药学上可接受的盐，其中所有变量如本文所定义。这些化合物是选择性 ROCK 抑制剂。本发明还涉及包含这些化合物的药物组合物以及使用这些化合物治疗心血管、平滑肌、肿瘤、神经病理、自身免疫、纤维化和/或炎症性疾病的方法。
• Indole and azaindole inhibitors of pad enzymes
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US11524959B1

  公开（公告）日：2022-12-13

  The present invention provides compounds of Formula (I) useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders, wherein each of Ring A, L, Q, R1, R2, R3, R4, R7, and R8 along with other variables are as defined herein.

  本发明提供了用作 PAD4 抑制剂的式 (I) 化合物、其组合物以及治疗 PAD4 相关疾病的方法，其中环 A、L、Q、R1、R2、R3、R4、R7 和 R8 中的每一个以及其他变量如本文所定义。
• [EN] USE OF CSE INHIBITORS FOR THE TREATMENT OF CUTANEOUS INJURIES OR CONDITIONS AND SLEEP-RELATED BREATHING DISORDERS<br/>[FR] UTILISATION D'INHIBITEURS DE CSE POUR LE TRAITEMENT DE LÉSIONS OU D'AFFECTIONS CUTANÉES ET DE TROUBLES RESPIRATOIRES DU SOMMEIL
  申请人：SOVA PHARMACEUTICALS INC

  公开号：WO2014018571A2

  公开（公告）日：2014-01-30
• LACTAMS AS INHIBITORS OF ROCK
  申请人：Bristol-Myers Squibb Company

  公开号：EP3268360B1

  公开（公告）日：2019-04-24
• DIAZASPIRO ROCK INHIBITORS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20210188848A1

  公开（公告）日：2021-06-24

  The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.